相关实验视频
Updated: Sep 19, 2025

13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
17.7K
人工智能在神经疾病的药物发现中的应用
1Collaborations Pharmaceuticals Inc., 1730 Varsity Drive, Suite 360, Raleigh, NC 27606-5228, USA.
概括
人工智能 (AI) 和机器学习加速了针对神经疾病的新药的发现. 这些先进的计算工具分析了庞大的数据集,以识别有前途的化合物和标,克服了药物开发的先前局限性.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 药物发现 药物发现 药物发现
背景情况:
- 神经系统疾病代表了1000多种疾病,具有重大的健康和经济影响.
- 目前用于神经疾病的药物开发面临着由于高成本和有限的疾病理解的挑战.
- 尽管经过数十年的研究,许多神经疾病的有效治疗或治愈仍然难以捉摸.
研究的目的:
- 审查人工智能 (AI) 在加速神经疾病药物发现中的多样化应用.
- 突出AI如何克服识别和开发新型治疗化合物的传统挑战.
- 探索人工智能的潜力,扩大可治疗的神经目标和疾病的范围.
主要方法:
- 利用现有的大规模数据集,包括高通量查数据,蛋白质晶体结构和分子特性 (例如,血脑屏障的透性).
- 利用计算工具,专注于机器学习和人工智能 (AI) 方法.
- 应用个人计算技术和复杂的端到端人工智能策略.
主要成果:
- 人工智能和机器学习提供了强大的能力,以加快新药分子的识别和发现.
- 这些技术使科学家能够更有战略性地缩小潜在的药物候选人进行测试.
- 人工智能有助于研究以前无法获得的目标和更广泛的神经疾病.
结论:
- 人工智能对实现对广泛的神经疾病的新发现和治疗具有重大前景.
- 人工智能在药物发现中的战略应用可以克服成本和知识障碍.
- 人工智能代表了解决神经疾病治疗中未得到满足的需求的变革性方法.
相关概念视频
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K

